Search results
Results from the WOW.Com Content Network
Antibiotics are the treatment of choice for bacterial pneumonia, with ventilation (oxygen supplement) as supportive therapy. The antibiotic choice depends on the nature of the pneumonia, the microorganisms most commonly causing pneumonia in the geographical region, and the immune status and underlying health of the individual.
Cefaclor is frequently used against bacteria responsible for causing skin infections, otitis media, urinary tract infections, and others. Cefaclor has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections: Gram positive aerobes - Staphylococci (including coagulase-positive, coagulase-negative, and penicillinase-producing strains ...
Additional consideration is given to the treatment setting; most patients are cured by oral medication, while others must be hospitalized for intravenous therapy or intensive care. Current treatment guidelines recommend a beta-lactam, like amoxicillin, and a macrolide, like azithromycin or clarithromycin, or a quinolone, such as levofloxacin.
Pneumonia: Visual disturbance, liver toxicity. [7] Spiramycin: Rovamycine: Mouth infections: Fidaxomicin: Dificid: Treatment of Clostridioides (formerly Clostridium) difficile infection. [8] May be more narrow-spectrum than vancomycin, resulting in less bowel microbiota alteration. [9] Nausea (11%), vomiting, and abdominal pain. [10]
Other than this and one other clinical trial into its efficacy as a treatment for pneumocystis pneumonia, [60] data on its use in both the treatment and prevention of pneumocystis pneumonia is significantly lacking. Toxoplasmosis: Yes: Prevention only: Yes: Clinical trials have confirmed its prophylactic and therapeutic utility in cases of ...
Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. [9] [10] Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA).
The FDA approved the drug on 11 September 2009 for complicated skin and skin structure infections . [3] Theravance has also submitted telavancin to the FDA in a second indication, nosocomial pneumonia, sometimes referred to as hospital-acquired pneumonia, or HAP. On 30 November 2012, an FDA advisory panel endorsed approval of a once-daily ...
Atovaquone is a medication used to treat or prevent: For pneumocystis pneumonia (PCP), [3] [4] it is used in mild cases, although it is not approved for treatment of severe cases. For toxoplasmosis, [5] the medication has antiparasitic and therapeutic effects. For malaria, it is one of the two components (along with proguanil) in the drug Malarone.